Cardiovasc drugs ther. impact factor
WebImpact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation Cardiovasc Drugs Ther. 2024 Oct;33(5):615-623. doi: 10.1007/s10557-019-06907-8. ... Risk Factors Stroke / diagnosis ... WebHypertension in the US Black population: risk factors, complications, and potential impact of central aortic pressure on effective treatment Cardiovasc Drugs Ther . 2012 …
Cardiovasc drugs ther. impact factor
Did you know?
WebIt is uncertain whether drug interactions can have a direct impact on clinical results, and only a few observational studies have been conducted. ... The global burden of cardiovascular diseases and risk factors: 2024 and beyond. J Am Coll Cardiol. (2024) ... Expert Rev Cardiovasc Ther. (2016) 14:991–9. doi: 10.1080/14779072.2016.1207528, ... WebApr 4, 2024 · Cardiovascular Drugs and Therapy is a careful and accurate guide for clinicians and researchers to navigate new products and therapies in cardiovascular pharmacology that will remain an essential and timeless resource. ... Impact factor … Volumes and issues. Volume 37 February - April 2024. April 2024, issue 2; February …
WebMay 27, 2024 · The impact score (IS) 2024 of Cardiovascular Therapeutics is 3.15, which is computed in 2024 as per its definition.Cardiovascular Therapeutics IS is increased by a factor of 0.75 and approximate percentage change is 31.25% when compared to preceding year 2024, which shows a rising trend. The impact score (IS), also denoted as Journal … WebSubstantial evidence shows that elevated plasma Lp(a) level is a heritable, independent, and possibly causal risk factor for ASCVD through its proatherogenic, proinflammatory, …
WebJan 1, 2024 · Cardiovascular Therapeutics is part of a partnership between Wiley and Hindawi and is now fully open access.Cardiovascular Therapeutics will remain a Wiley title but will be published and hosted … WebCardiovasc is a medicine available in a number of countries worldwide. A list of US medications equivalent to Cardiovasc is available on the Drugs.com website. ...
WebCirc Cardiovasc Qual Outcomes. 2009;2(6):607–615. 27. Zeller T, Krankenberg H, Steinkamp H, et al. One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial. J Endovasc Ther. 2009;16(6):653–662. 28.
WebScope. Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke ... primary risk factor definitionWebCardiovasc Drugs Ther. 2016;30:539–550. 35. Birnbaum GD, Birnbaum I, Ye Y, Birnbaum Y. Statin-induced cardioprotection against ischemia-reperfusion injury: potential drug–drug interactions. Lesson to be learnt by translating results from animal models to the clinical settings. Cardiovasc Drugs Ther. 2015;29:461–467. 36. primary risk factor for parkinson\\u0027s diseaseprimary rights of constitution of indiaWebInitial statin dose after myocardial infarction and long-term cardiovascular outcomes. Aims Effective statin therapy is a cornerstone of secondary prevention after myocardial infarction (MI). Real-life statin dosing is nevertheless suboptimal and largely determined early after MI. We studied long-term outcome impact of initial statin dose after MI. players on the dream teamWebJournal impact factor : 0.91 ; Average acceptance to publication time (5-7 days) ... Therapeutics is additionally concerned with the identification and validation of biomarkers to either help drug improvement, or permit a stratified medicine approach in patients. ... J Cardiovasc Med Ther: 5(5): 1-1 . Radiofrequency control in cardio fibrillation. players on the hawksWebCardiovasc Drugs Ther. 2002 Sep;16(5):391-9. doi: 10.1023/a:1022130217463. ... Genetic factors, certain drugs and renal impairment may also contribute. Homocysteine has several potentially deleterious vascular actions. These include increased oxidant stress, impaired endothelial function, stimulation of mitogenesis, and induction of thrombosis ... primary risk factor for alzheimer\u0027s diseaseWebNov 16, 2012 · Heart rate (HR) is a precisely regulated variable, which plays a critical role in health and disease. Elevated resting HR is a significant predictor of all-cause and cardiovascular mortality in the general population and patients with cardiovascular disease (CVD). β-blocking drugs exert negative effects on regional myocardial blood flow and … primary riser pole